Comment
doi: 10.1002/cncr.33608.
Triple Chemotherapy Combination Improves Metastatic Colorectal Cancer Outcomes
- PMID: 33914943
- DOI: 10.1002/cncr.33608
Item in Clipboard
Comment
Triple Chemotherapy Combination Improves Metastatic Colorectal Cancer Outcomes
Cancer.
.
Free article
No abstract available
Comment on
-
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).J Clin Oncol. 2021 Feb 1;39(4):285-294. doi: 10.1200/JCO.20.01994. Epub 2020 Dec 23. J Clin Oncol. 2021. PMID: 33356422 Free PMC article. Clinical Trial.
Similar articles
-
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105. JAMA. 2017. PMID: 28632865 Free PMC article. Clinical Trial.
-
Tolerability profile of bevacizumab in metastatic colorectal cancer: about a Medical Department experience.Pan Afr Med J. 2016 Oct 26;25:118. doi: 10.11604/pamj.2016.25.118.2266. eCollection 2016. Pan Afr Med J. 2016. PMID: 28292081 Free PMC article.
-
Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.Cancer Med. 2019 Jul;8(7):3437-3446. doi: 10.1002/cam4.2235. Epub 2019 May 15. Cancer Med. 2019. PMID: 31090176 Free PMC article.
-
Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review.Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):322-325. Acta Gastroenterol Belg. 2019. PMID: 31314196 Review.
-
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer.Target Oncol. 2016 Jun;11(3):293-308. doi: 10.1007/s11523-015-0400-y. Target Oncol. 2016. PMID: 26687849 Free PMC article. Review.
Cited by
-
A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms.Food Sci Nutr. 2023 Aug 28;11(11):6789-6801. doi: 10.1002/fsn3.3645. eCollection 2023 Nov. Food Sci Nutr. 2023. PMID: 37970406 Free PMC article. Review.
-
B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.Sci Rep. 2024 Apr 2;14(1):7733. doi: 10.1038/s41598-024-58424-w. Sci Rep. 2024. PMID: 38565963 Free PMC article.
-
Most eligible candidates for primary tumor resection among metastatic colorectal cancer patients: a SEER-based population analysis.Transl Cancer Res. 2025 Jul 30;14(7):4381-4398. doi: 10.21037/tcr-2025-1084. Epub 2025 Jul 24. Transl Cancer Res. 2025. PMID: 40792154 Free PMC article.
-
Role of Ginseng, Quercetin, and Tea in Enhancing Chemotherapeutic Efficacy of Colorectal Cancer.Front Med (Lausanne). 2022 Jun 20;9:939424. doi: 10.3389/fmed.2022.939424. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35795631 Free PMC article. Review.
References
-
- Kopetz S, Guthrie KA, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer. J Clin Oncol. 2021;39:285-294. doi:10.1200/JCO.20.01994
-
- Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381:1632-1643. doi:10.1056/NEJMoa1908075
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
